A Phase 2 interventional study of aminopterin and L-asparaginase in Acute Lymphocytic Leukemia, sponsored by Rutgers, The State University of New Jersey. Completed at 2 sites in United States. Open to participants aged 1 Year to 30 Years. Per ClinicalTrials.gov, last updated 2014-06-09.
Sponsored by Rutgers, The State University of New Jersey · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 187 studies testing cyclophosphamide in Precursor Cell Lymphoblastic Leukemia-Lymphoma — 28 open to participants now, 45 under way, 7 of them phase 3. Cyclophosphamide · Precursor Cell Lymphoblastic Leukemia-Lymphoma.
Among the 187 studies testing cyclophosphamide in Precursor Cell Lymphoblastic Leukemia-Lymphoma, this one is the 67th largest by enrollment of the 179 interventional ones that give a count, is one of 4 that started in 2001, is one of 104 in phase 2, and was the 45th registered.
2,586 studies on the registry are indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma; 471 are open to participants now.
Browse Precursor Cell Lymphoblastic Leukemia-Lymphoma studies →28 of the 187 studies testing cyclophosphamide in Precursor Cell Lymphoblastic Leukemia-Lymphoma are open now, in 12 countries. Recruiting first, the newest first:
National Cancer Institute (NCI) · Sites in United States
Ages 18–120
St. Jude Children's Research Hospital · Sites in United States
Ages up to 21
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages up to 26
Bambino Gesù Hospital and Research Institute · Sites in Austria, Czechia, Denmark and 6 more countries
Ages 3 mo–25 yrs
Princess Maxima Center for Pediatric Oncology · Sites in Austria, Belgium, Denmark and 11 more countries
Ages 1–21
By country, each count listing its studies:
Cyclophosphamide: first FDA approval 1959 (CYTOXAN). What it is approved for, and how studies give it, is on its page →
Of the 369 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 96 (26%) set no upper age limit and 257 (70%) stop at 75 or younger; 247 take children under 18; 29 take healthy volunteers.
This study: 1 Year to 30 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
187 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 51 · Phase 2 123 · Phase 3 19 · Phase 4 2
First in 1988; this study’s year is marked. 4 started in 2001.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 60 is above the median of 40 across 1,953 interventional studies indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma.
Median enrollment 47 across the 179 interventional studies. Of the 126 that completed or were terminated, 67 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 187 have an industry lead sponsor. The 10 most frequent:
Rutgers, The State University of New Jersey is the lead sponsor of 507 studies on the registry; 132 are open to participants now.
Of its 39 completed or terminated interventional studies of FDA-regulated products, 31 (79%) have results posted.
Rutgers, The State University of New Jersey has 4 studies filed under Precursor Cell Lymphoblastic Leukemia-Lymphoma — fewer than ten, so there is no comparison to draw.
13 of the studies testing cyclophosphamide in Precursor Cell Lymphoblastic Leukemia-Lymphoma that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05681260Phase 3Children's Cancer Group, ChinaCapizzi Escalating Methotrexate Versus High Dose Methotrexate in Children With Newly Diagnosed T-cell Lymphoblastic Lymphoma (T-LBL) | 2026-12-31 |
| NCT06001385Center for International Blood and Marrow Transplant ResearchHLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis | 2026-12-24 |
| NCT05909059Northside Hospital, Inc.CAR T-cell Therapy in Patients With Renal Dysfunction | 2026-12-31 |
| NCT05364762City of Hope Medical CenterAdding Itacitinib to Cyclophosphamide and Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Hematopoietic Stem Cell Transplants | 2027-03-25 |
| NCT04872595Memorial Sloan Kettering Cancer CenterA Modified Dose of Rabbit Anti-thymocyte Globulin (rATG) in Children and Adults Receiving Treatment to Help Prepare Their Bodies for a Bone Marrow Transplant | 2027-04 |
Add all 13 to your calendar (.ics) → With an account.
Among the 187 studies testing cyclophosphamide in Precursor Cell Lymphoblastic Leukemia-Lymphoma, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this research study is to identify better ways to treat children and young adults with acute lymphocytic leukemia (ALL). At the same time, doctors hope to define methods to identify those patients at higher risk for certain side effects, as well as those who are at higher risk for relapse of their leukemia.
Outline of Therapy:
Combinations of chemotherapy drugs will be given orally, intravenously and intrathecally (directly into the cerebrospinal fluid by spinal tap) over a period of roughly two and a half years.
Therapy will be divided into five phases:
Induction (4 weeks): chemotherapy given to produce a clinical remission (defined by normal blood counts, with the absence of leukemia cells in the blood and fewer than 5% leukemia cells in the bone marrow).
Consolidation (11 weeks): chemotherapy given to consolidate the remission. Delayed Intensification (7 weeks) Intensive chemotherapy aimed at killing any resistant leukemia cells will be given only for patients at high risk of relapse.
Intensive Continuation (approximately 1 year): Eight week cycles of chemotherapy, given eight times.
Continuation (final year of therapy): Eight week cycles of largely oral chemotherapy, with one clinic visit for a lumbar puncture every eight weeks.
Irradiation: radiation will be given in the middle of intensive continuation to the head and spine of those patients who have leukemia cells found in the cerebrospinal fluid at the time of diagnosis.
Follow-up: After the conclusion of therapy, there will be periodic office visits, initially monthly, then gradually spaced out to annual visits. The purpose of these visits is to evaluate for late side-effects of therapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
6-MERCAPTOPURINE DAUNOMYCIN DEXAMETHASONE Triple Intrathecal Therapy (ITT) L-ASPARAGINASE VINCRISTINE METHOTREXATE Leucovorin
Drug: L-asparaginase · Drug: daunomycin · Drug: dexamethasone · Drug: 6-mercaptopurine · Drug: methotrexate · Drug: vincristine · Drug: Triple Intrathecal Therapy (MTX, Cytarabine, Hydrocortisone) · Drug: Leucovorin
6-MERCAPTOPURINE DAUNOMYCIN DEXAMETHASONE Triple Intrathecal Therapy (ITT) L-ASPARAGINASE VINCRISTINE 6-THIOGUANINE CYTARABINE AMINOPTERIN CYCLOPHOSPHAMIDE ARABINOSIDE-C
Drug: aminopterin · Drug: L-asparaginase · Drug: cyclophosphamide · Drug: cytarabine · Drug: daunomycin · Drug: dexamethasone · Drug: 6-mercaptopurine · Drug: 6-thioguanine · Drug: vincristine · Drug: Triple Intrathecal Therapy (MTX, Cytarabine, Hydrocortisone) · Drug: Leucovorin
Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
Percentage of Patients With ALL at High Risk of Relapse (Arm 2) Who Were Relapse-free at 5 Years
This measure looks at the percentage of patients on Arm 2 who did not experience a relapse at 5 years, where relapse is defined as the presence of progressive disease after the achievement of a complete remission.
Time frame: 5 years
To Measure 5-methyltetrahydrofolate, Aminopterin and Methotrexate Uptake in Leukemic Blasts Isolated at Diagnosis
Time frame: 5 years
59 patients with ALL were enrolled between March, 2001 and September, 2005 at the Cancer Institute of New Jersey (outpatient clinical research facility) and 1 patient was enrolled at Jersey Shore University Medical Center (a community hospital).
| Milestone | Arm 1 Standard Risk | Arm 2 High Risk |
|---|---|---|
| Started | 21 | 39 |
| Completed | 20 | 34 |
| Not completed | 1 | 5 |
| Withdrew: Withdrawal by subject | 0 | 2 |
| Withdrew: Death | 1 | 2 |
| Withdrew: Lack of efficacy | 0 | 1 |
| Milestone | Arm 1 Standard Risk | Arm 2 High Risk |
|---|---|---|
| Started | 20 | 34 |
| Completed | 20 | 29 |
| Not completed | 0 | 5 |
| Withdrew: Patient moved to another state | 0 | 1 |
| Withdrew: Adverse event | 0 | 1 |
| Withdrew: Lack of efficacy | 0 | 2 |
| Withdrew: Not documented | 0 | 1 |
| Milestone | Arm 1 Standard Risk | Arm 2 High Risk |
|---|---|---|
| Started | 20 | 29 |
| Completed | 20 | 29 |
| Not completed | 0 | 0 |
| Milestone | Arm 1 Standard Risk | Arm 2 High Risk |
|---|---|---|
| Started | 20 | 29 |
| Completed | 19 | 26 |
| Not completed | 1 | 3 |
| Withdrew: Death | 1 | 0 |
| Withdrew: Lack of efficacy | 0 | 3 |
| Milestone | Arm 1 Standard Risk | Arm 2 High Risk |
|---|---|---|
| Started | 19 | 26 |
| Completed | 19 | 26 |
| Not completed | 0 | 0 |
This measure looks at the percentage of patients on Arm 2 who did not experience a relapse at 5 years, where relapse is defined as the presence of progressive disease after the achievement of a complete remission.
| percentage of participants | Arm 2 High Risk |
|---|---|
| Percentage of Patients With ALL at High Risk of Relapse (Arm 2) Who Were Relapse-free at 5 Years | 64.9 |
No measurements were reported for this outcome.
Collected over 7 years, 6 months. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm 1 Standard Risk | — | 20/21 (95.2%) | 21/21 (100%) |
| Arm 2 High Risk | — | 36/39 (92.3%) | 39/39 (100%) |
| Event | Arm 1 Standard Risk | Arm 2 High Risk |
|---|---|---|
| Febrile neutropeniaInfections and infestations | 16/21 | 17/39 |
| PlateletsBlood and lymphatic system disorders | 5/21 | 5/39 |
| Infection without neutropeniaInfections and infestations | 3/21 | 1/39 |
| Pneumonitis/pulmonary infiltratesRespiratory, thoracic and mediastinal disorders | 3/21 | 2/39 |
| Muscle weakness (not due to neuropathy)Musculoskeletal and connective tissue disorders | 0/21 | 5/39 |
| DyspneaRespiratory, thoracic and mediastinal disorders | 2/21 | 1/39 |
| Infection with unknown ANCInfections and infestations | 1/21 | 3/39 |
| DehydrationGastrointestinal disorders | 0/21 | 3/39 |
| AnorexiaGeneral disorders | 0/21 | 3/39 |
| HemoglobinBlood and lymphatic system disorders | 1/21 | 3/39 |
| Event | Arm 1 Standard Risk | Arm 2 High Risk |
|---|---|---|
| FeverGeneral disorders | 12/21 | 15/39 |
| VomitingGastrointestinal disorders | 2/21 | 7/39 |
| Headache - Pain-HeadGeneral disorders | 0/21 | 7/39 |
| Allergic reaction/hypersensitivityImmune system disorders | 3/21 | 0/39 |
| Other ToxicityGeneral disorders | 3/21 | 5/39 |
| DehydrationGastrointestinal disorders | 1/21 | 5/39 |
| Infection with unknown ANCInfections and infestations | 1/21 | 4/39 |
| Abdominal pain or crampingGastrointestinal disorders | 1/21 | 4/39 |
| Stomatitis / pharyngitisGastrointestinal disorders | 1/21 | 4/39 |
| HemoglobinBlood and lymphatic system disorders | 2/21 | 0/39 |
| Age, Categorical(Participants) | Arm 1 Standard Risk | Arm 2 High Risk | Total |
|---|---|---|---|
| <=18 years | 21 | 30 | 51 |
| Between 18 and 65 years | 0 | 9 | 9 |
| >=65 years | 0 | 0 | 0 |
| Age, Continuous(years) | Arm 1 Standard Risk | Arm 2 High Risk | Total |
|---|---|---|---|
| Mean | 3.71 ± 1.77 | 16 ± 9.8 | 11.7 ± 9.89 |
| Sex: Female, Male(Participants) | Arm 1 Standard Risk | Arm 2 High Risk | Total |
|---|---|---|---|
| Female | 11 | 18 | 29 |
| Male | 10 | 21 | 31 |
| Region of Enrollment(participants) | Arm 1 Standard Risk | Arm 2 High Risk | Total |
|---|---|---|---|
| United States | 21 | 39 | 60 |
The record gives a start of Feb 2001, a primary completion of Sep 2008 and a completion of Sep 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2014, 5 years 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Aminopterin · Cyclophosphamide · Cytarabine · Methotrexate · Thioguanine
Precursor Cell Lymphoblastic Leukemia-Lymphoma →
Rutgers, The State University of New Jersey →